Copathology in Progressive Supranuclear Palsy: Does It Matter?
Milica Jecmenica LukicCarolin KurzGesine RespondekOriol Grau-RiveraYaroslau ComptaEllen GelpiClaire Troakesnull nullJohn C van SwietenArmin GieseSigrun RoeberThomas ArzbergerGünter U HöglingerPublished in: Movement disorders : official journal of the Movement Disorder Society (2020)
In PSP, concomitant neurodegenerative proteinopathies or cerebrovascular diseases are frequent, but generally mild in severity. Our data confirmed that four repeat tau is still the most relevant target for PSP, whereas the impact of copathologies on progression rate appears to be of less importance. This is relevant information for the development of disease-modifying therapies. © 2020 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.